News

Scientists at Karolinska Institutet and Karolinska University Hospital have discovered a new explanation for severe early infant epilepsy.

Scientists at Queen’s are developing a potential revolutionary new treatment for Sepsis and Acute Respiratory Distress Syndrome (ARDS), which are among the leading causes of death in hospitalized patients in the UK.

Because mutation is so rare, expensive screening makes it impractical for overall population, UCLA research finds.

The company have announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule.

Novartis have announced that the European Commission has approved the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Dr Hutchison brings a wealth of experience of clinical drug development in both big pharma and the biotech sector.

STA subsidiary receives approval for the manufacture of the GMP intermediate of a branded commercial drug.

Significantly enhances Celgene's I&I franchise with the addition of Ozanimod, potentially a best-in-class oral agent in Phase III trials for inflammatory bowel disease and multiple sclerosis.

US and EU regulatory submission planned in moderate-to-severe psoriasis in Q4 2015.